BC
LGND icon

Broadfin Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Broadfin Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-318,997
Closed -$10.6M – 85
2014
Q4 		$10.6M Buy
+318,997
New +$10.4M 0.92% 31

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Broadfin Capital's LGND Position: Q1 2015 in Review

Broadfin Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2015, closing a stake of 318,997 shares — an estimated $10.6M sold.

Broadfin Capital first reported a position in LGND in Q4 2014 and held it in 1 quarter. The position peaked at $10.6M in Q4 2014. 187 funds tracked by Wall St. Rank hold LGND as of Q1 2015.

  • Broadfin Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Broadfin Capital sold 318,997 Ligand Pharmaceuticals shares in Q1 2015, an estimated $10.6M.
  • Broadfin Capital first reported a position in Ligand Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Broadfin Capital's Ligand Pharmaceuticals position peaked at $10.6M in Q4 2014.
  • 187 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2015.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.